Inovio 
Welcome,         Profile    Billing    Logout  
 27 Products   14 Diseases   27 Products   13 Trials   837 News 


«123456789»
  • ||||||||||  INO-A002 / Inovio
    Enrollment closed:  A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) -  Oct 19, 2021   
    P1,  N=30, Active, not recruiting, 
    IFNγ T cell responses were fully maintained against all variants tested. Recruiting --> Active, not recruiting
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute, Coronavirus Vaccine / The Peter Doherty Institute for Infection and Immunity
    Journal:  Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein. (Pubmed Central) -  Oct 9, 2021   
    Through this approach, supported by biomolecular modelling of this mutation and the commonly-associated P314L mutation in the RNA-dependent RNA polymerase, we have shown that there is no experimental evidence to support this speculation. We additionally demonstrate that the putative elastase cleavage site introduced by the D614G mutation is unlikely to be accessible to proteases.
  • ||||||||||  neoantigen DNA vaccine / Washington University School of Medicine in St. Louis, AstraZeneca
    Trial completion date, Trial primary completion date:  Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov) -  Aug 18, 2021   
    P1,  N=12, Recruiting, 
    Trial completion date: Sep 2023 --> Jun 2024 | Trial primary completion date: Sep 2023 --> Jun 2024 Trial completion date: Jul 2024 --> Jul 2023 | Trial primary completion date: Oct 2023 --> Aug 2022
  • ||||||||||  INO-A002 / Inovio
    Trial completion date, Trial primary completion date:  A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) -  Aug 18, 2021   
    P1,  N=30, Recruiting, 
    Trial completion date: Jul 2024 --> Jul 2023 | Trial primary completion date: Oct 2023 --> Aug 2022 Trial completion date: Feb 2023 --> Oct 2022 | Trial primary completion date: Feb 2023 --> Oct 2022
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute
    Preclinical, Journal:  Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets. (Pubmed Central) -  Aug 4, 2021   
    Neutralisation titres against G614 and 501Y.V1 were comparable, but titres against the 501Y.V2 variant were approximately 4-fold lower, similar to results reported with other nucleic acid vaccines and supported by in silico biomolecular modelling. The results confirm that the vaccine-induced neutralising antibodies generated by INO-4800 remain effective against current variants-of-concern, albeit with lower neutralisation titres against 501Y.V2 similar to other leading nucleic acid-based vaccines.
  • ||||||||||  INO-A002 / Inovio
    Enrollment open:  A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) -  Jul 22, 2021   
    P1,  N=30, Recruiting, 
    The results confirm that the vaccine-induced neutralising antibodies generated by INO-4800 remain effective against current variants-of-concern, albeit with lower neutralisation titres against 501Y.V2 similar to other leading nucleic acid-based vaccines. Active, not recruiting --> Recruiting
  • ||||||||||  bizalimogene ralaplasmid (VGX-3100) / Inovio
    Journal:  Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL. (Pubmed Central) -  Jul 7, 2021   
    In women with cervical HSIL who responded to VGX-3100 and were able to avoid surgery, clinical outcomes were comparable to the placebo control group which underwent conventional surgical treatment. These findings extend the understanding of the durability of the treatment effect of VGX-3100 up to 1.5 y and support that VGX-3100 could be used as an alternative to surgery.
  • ||||||||||  bizalimogene ralaplasmid (VGX-3100) / Inovio
    Clinical, Journal:  Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population. (Pubmed Central) -  Jun 22, 2021   
    The primary endpoint was met with 89.9% of RF recipients and 97.2% of FF recipients reaching a ≥2-fold rise in SFU/10 PBMC, 2 weeks following the last dose; RF was statistically non-inferior to FF (p = .022).A systemic, immunologic approach has the potential to fill a critical gap in the ability to treat men and women with high grade HPV diseases. These safety and immunogenicity data are supportive of the continued development of a refrigerated formulation of VGX-3100.
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute
    Preclinical, Journal:  A novel mouse AAV6 hACE2 transduction model of wild-type SARS-CoV-2 infection studied using synDNA immunogens. (Pubmed Central) -  Jun 16, 2021   
    We validated this model using a previously described synthetic DNA vaccine plasmid, INO-4800 (pS)...One immunization resulted in 50% protection and two immunizations were completely protective. Overall, the AAV6.2FF-hACE2 mouse transduction model represents an easily accessible, genetically diverse mouse model for wild-type SARS-CoV-2 infection and preclinical evaluation of potential interventions.
  • ||||||||||  PENNVAX-GP (HIV DNA vaccine) / Inovio
    Journal:  Robust antibody and cellular responses induced by DNA-only vaccination for HIV. (Pubmed Central) -  Jun 10, 2021   
    P1
    PENNVAX®-GP DNA induced robust cellular and humoral immune responses, demonstrating that immunogenicity of DNA vaccines can be enhanced by EP route and inclusion of pIL-12. ID/EP was dose-sparing, inducing equivalent, or in some aspects superior, immune responses compared to IM/EP.
  • ||||||||||  bizalimogene ralaplasmid (VGX-3100) / Inovio
    Trial completion:  REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (clinicaltrials.gov) -  Jun 7, 2021   
    P3,  N=201, Completed, 
    Analysis indicated that CD38 and perforin co-positive CD8 T cell frequency correlated with attenuated PSA rise (p = 0.05, n = 50). Active, not recruiting --> Completed